We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CD73

News List

An Emerging Target for Solid Tumors -- CD73 Development in China PharmaSources/Yefenghong
June 16, 2021
CD73, also known as Ecto-5′-Nucleotidase, is a cell surface enzyme, which is widely expressed on the surface of endothelial cells of human bodies, lymphocytes such as Treg and other cells.
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. prnasia
February 07, 2021
I-Mab announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors.
Researchers identify immune-suppressing target in glioblastoma worldpharmanews
December 24, 2019
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with ...